A novel computational drug screening strategy combined with lab experiments suggest that pralatrexate, a chemotherapy medication originally developed to treat lymphoma, could potentially be repurposed to treat Covid-19. Haiping Zhang of the Shenzhen Institutes of Advanced Technology in Shenzhen, China, and colleagues present these findings.
Dr. Michael Teitell is director of the UCLA Jonsson Comprehensive Cancer Center. Scientists from the UCLA Jonsson Comprehensive Cancer Center have developed a simple, high-throughput method for transferring isolated mitochondria and their associated mitochondrial DNA into mammalian cells. This approach enables researchers to tailor a key genetic component of cells, to study and potentially treat […]
One of the physiopathological characteristics of COVID-19 that has most baffled the scientific and medical community is what is known as “silent hypoxemia” or “happy hypoxia”. Patients suffering this phenomenon, the causes of which are still unknown, have severe pneumonia with markedly decreased arterial blood oxygen levels (known as hypoxemia). However, they do not report […]
A new synthetic probe offers a safe and straightforward approach for visualizing chromosome tips in living cells. The probe was designed by scientists at the Institute for Integrated Cell-Material Science (iCeMS) and colleagues at Kyoto University, and could advance research into aging and a wide range of diseases, including cancers.
ZTA Biotech, a Budapest-based biotech startup has announced the breakthrough development of a COVID-19 antibody (IgG) test using the ELISA protocol. This new detection method represents a great step forward in determining if patients have had COVID-19 and if they might still have immunity to the disease. Early results have proven 100% in specificity after testing 280 samples, and 100% sensitivity by testing 260 samples of recovered and symptomatic patients.
One of the conundrums presented by COVID-19 is that it is not uncommon for patients to present with remarkably low oxygen saturation levels but with very little breathlessness. Additionally, it has been noted that there is an additional risk of stroke in COVID-19 patients (and COVID-19-recovered patients) and that they seem to have what is being referred to as ‘sticky blood’. A recent paper by Professor Yost (Department of Pediatrics, University of Utah School of Medicine, UT, USA) and colleagues ‘Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome’ discusses the role that neutrophil extracellular traps (NETs) can play in the development of these symptoms and prothrombotic disease outcomes. CLI was very fortunate to catch up with Professor Yost to learn more about NETs and their effects in COVID-19 and other conditions.
by Dr Madeleen Bosma
Despite intensive anticoagulation therapy and improved mechanical characteristics of the current systems, hemolysis and clot formation are frequent complications in extracorporeal life support (ECLS/ECMO), which is the standard rescue treatment in patients with severely impaired cardiac and/or pulmonary function. The laboratory aspects of monitoring of hemolysis and hypercoagulation in this patient group are discussed in this short review.
by Dr Andrew Lane
The emergence of SARS-CoV-2 and its global proliferation has spurred unprecedented efforts by academia and the in vitro diagnostics industry to develop rapid tests that can be used for point-of-care (POC) testing. At the time of writing, over 200 rapid test kits are under development or have already been commercialized for use. Yet, owing to relaxation of regulatory standards and the unprecedented pace at which tests have been developed, many have not been adequately assessed. In this article, Dr Andy Lane explains the role of POC diagnostics for COVID-19 and the improvements needed for their widespread use, including the importance of high-quality reagents.
by Dr Jacqueline Gosink
The autoimmunogenic myositides (idiopathic inflammatory myopathies, IIM) constitute a group of systemic autoimmune rheumatic diseases that are characterized by chronic inflammation of muscles. Unfortunately, the general misdiagnosis rate is high resulting in a delay to diagnosis of several years. Moreover, a significant proportion of patients with IIM suffer from a generalized feeling of severe illness due to the damage caused by both the disease and its treatment. Autoantibodies are useful biomarkers to differentiate clinically indistinguishable subforms of IIM. Despite the low prevalences and isolated occurrence of many autoantibodies in IIM, they constitute the basis for serological diagnostics. The diagnostic information is maximized by employing comprehensive multiparametric assays covering both myositis-specific and myositis-associated autoantibodies.
by Pauline Griffeuille and Dr Sylvain Dulaurent
Mass spectrometry (MS) can be combined with a number of chromatographic separation and ionization methods, which results in powerful technologies for both qualitative and quantitative molecular analysis. CLI caught up with Dr Bhattacharyya (Thermo Fisher’s Senior Manager for Clinical Research and Toxicology) to find out more about the past, present and potential future uses of MS in clinical science and diagnostics.
November 2025
Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.